<?xml version="1.0" encoding="UTF-8"?>
<TEI xml:space="preserve" xmlns="http://www.tei-c.org/ns/1.0" 
xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" 
xsi:schemaLocation="http://www.tei-c.org/ns/1.0 /data/rsg/nlp/juanmoo1/bin/grobid-0.6.1/grobid-home/schemas/xsd/Grobid.xsd"
 xmlns:xlink="http://www.w3.org/1999/xlink">
	<teiHeader xml:lang="en">
		<fileDesc>
			<titleStmt>
				<title level="a" type="main">Addition of docetaxel to hormonal therapy in low-and high-burden metastatic hormone sensitive prostate cancer: long-term survival results from the STAMPEDE trial</title>
			</titleStmt>
			<publicationStmt>
				<publisher/>
				<availability status="unknown"><licence/></availability>
				<date type="published" when="2019-09-27">27 September 2019</date>
			</publicationStmt>
			<sourceDesc>
				<biblStruct>
					<analytic>
						<author role="corresp">
							<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">N</forename><forename type="middle">W</forename><surname>Clarke</surname></persName>
							<email>noel.clarke@christie.nhs.uk</email>
							<affiliation key="aff0">
								<orgName type="department">Department of Urology</orgName>
								<orgName type="institution">The Christie and Salford Royal NHS Foundation Trusts</orgName>
								<address>
									<settlement>Manchester</settlement>
								</address>
							</affiliation>
						</author>
						<author>
							<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">A</forename><surname>Ali</surname></persName>
							<affiliation key="aff1">
								<orgName type="department">Division of Cancer Sciences</orgName>
								<orgName type="laboratory">Genito-Urinary Cancer Research Group</orgName>
								<orgName type="institution">The University of Manchester</orgName>
								<address>
									<settlement>Manchester</settlement>
								</address>
							</affiliation>
						</author>
						<author>
							<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">F</forename><forename type="middle">C</forename><surname>Ingleby</surname></persName>
							<affiliation key="aff2">
								<orgName type="department">Institute of Clinical Trials and Methodology</orgName>
								<orgName type="laboratory">MRC Clinical Trials Unit at UCL</orgName>
								<orgName type="institution">UCL</orgName>
								<address>
									<settlement>London</settlement>
								</address>
							</affiliation>
							<affiliation key="aff3">
								<orgName type="department">London School of Hygiene and Tropical Medicine</orgName>
								<address>
									<settlement>London</settlement>
								</address>
							</affiliation>
						</author>
						<author>
							<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">A</forename><surname>Hoyle</surname></persName>
							<affiliation key="aff0">
								<orgName type="department">Department of Urology</orgName>
								<orgName type="institution">The Christie and Salford Royal NHS Foundation Trusts</orgName>
								<address>
									<settlement>Manchester</settlement>
								</address>
							</affiliation>
						</author>
						<author>
							<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">C</forename><forename type="middle">L</forename><surname>Amos</surname></persName>
							<affiliation key="aff2">
								<orgName type="department">Institute of Clinical Trials and Methodology</orgName>
								<orgName type="laboratory">MRC Clinical Trials Unit at UCL</orgName>
								<orgName type="institution">UCL</orgName>
								<address>
									<settlement>London</settlement>
								</address>
							</affiliation>
						</author>
						<author>
							<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">G</forename><surname>Attard</surname></persName>
							<affiliation key="aff4">
								<orgName type="institution">UCL Cancer Institute</orgName>
								<address>
									<settlement>London</settlement>
								</address>
							</affiliation>
						</author>
						<author>
							<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">C</forename><forename type="middle">D</forename><surname>Brawley</surname></persName>
							<affiliation key="aff2">
								<orgName type="department">Institute of Clinical Trials and Methodology</orgName>
								<orgName type="laboratory">MRC Clinical Trials Unit at UCL</orgName>
								<orgName type="institution">UCL</orgName>
								<address>
									<settlement>London</settlement>
								</address>
							</affiliation>
						</author>
						<author>
							<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">J</forename><surname>Calvert</surname></persName>
							<affiliation key="aff2">
								<orgName type="department">Institute of Clinical Trials and Methodology</orgName>
								<orgName type="laboratory">MRC Clinical Trials Unit at UCL</orgName>
								<orgName type="institution">UCL</orgName>
								<address>
									<settlement>London</settlement>
								</address>
							</affiliation>
						</author>
						<author>
							<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">S</forename><surname>Chowdhury</surname></persName>
							<affiliation key="aff5">
								<orgName type="laboratory">Guy&apos;s and Saint Thomas&apos; NHS Foundation Trust</orgName>
								<address>
									<settlement>London</settlement>
								</address>
							</affiliation>
						</author>
						<author>
							<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">A</forename><surname>Cook</surname></persName>
							<affiliation key="aff2">
								<orgName type="department">Institute of Clinical Trials and Methodology</orgName>
								<orgName type="laboratory">MRC Clinical Trials Unit at UCL</orgName>
								<orgName type="institution">UCL</orgName>
								<address>
									<settlement>London</settlement>
								</address>
							</affiliation>
						</author>
						<author>
							<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">W</forename><surname>Cross</surname></persName>
							<affiliation key="aff6">
								<orgName type="institution">St James University Hospital</orgName>
								<address>
									<settlement>Leeds</settlement>
								</address>
							</affiliation>
						</author>
						<author>
							<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">D</forename><forename type="middle">P</forename><surname>Dearnaley</surname></persName>
							<affiliation key="aff7">
								<orgName type="department">Institute of Cancer Research</orgName>
								<address>
									<settlement>Sutton-London</settlement>
								</address>
							</affiliation>
						</author>
						<author>
							<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">H</forename><surname>Douis</surname></persName>
							<affiliation key="aff8">
								<orgName type="department">Department of Radiology</orgName>
								<orgName type="institution">University Hospitals Birmingham NHS Foundation Trust</orgName>
								<address>
									<settlement>Birmingham</settlement>
								</address>
							</affiliation>
						</author>
						<author>
							<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">D</forename><surname>Gilbert</surname></persName>
							<affiliation key="aff2">
								<orgName type="department">Institute of Clinical Trials and Methodology</orgName>
								<orgName type="laboratory">MRC Clinical Trials Unit at UCL</orgName>
								<orgName type="institution">UCL</orgName>
								<address>
									<settlement>London</settlement>
								</address>
							</affiliation>
						</author>
						<author>
							<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">S</forename><surname>Gillessen</surname></persName>
							<affiliation key="aff9">
								<orgName type="department">Division of Cancer Sciences</orgName>
								<orgName type="institution">The University of Manchester</orgName>
								<address>
									<settlement>Manchester</settlement>
								</address>
							</affiliation>
						</author>
						<author>
							<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">R</forename><forename type="middle">J</forename><surname>Jones</surname></persName>
							<affiliation key="aff10">
								<orgName type="institution" key="instit1">Beatson West of Scotland Cancer Centre</orgName>
								<orgName type="institution" key="instit2">University of Glasgow</orgName>
								<address>
									<settlement>Glasgow</settlement>
								</address>
							</affiliation>
						</author>
						<author>
							<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">R</forename><forename type="middle">E</forename><surname>Langley</surname></persName>
							<affiliation key="aff2">
								<orgName type="department">Institute of Clinical Trials and Methodology</orgName>
								<orgName type="laboratory">MRC Clinical Trials Unit at UCL</orgName>
								<orgName type="institution">UCL</orgName>
								<address>
									<settlement>London</settlement>
								</address>
							</affiliation>
						</author>
						<author>
							<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">A</forename><surname>Macnair</surname></persName>
							<affiliation key="aff2">
								<orgName type="department">Institute of Clinical Trials and Methodology</orgName>
								<orgName type="laboratory">MRC Clinical Trials Unit at UCL</orgName>
								<orgName type="institution">UCL</orgName>
								<address>
									<settlement>London</settlement>
								</address>
							</affiliation>
						</author>
						<author>
							<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Z</forename><surname>Malik</surname></persName>
							<affiliation key="aff11">
								<orgName type="institution">The Clatterbridge Cancer Centre NHS Foundation Trust</orgName>
								<address>
									<settlement>Liverpool</settlement>
								</address>
							</affiliation>
						</author>
						<author>
							<persName xmlns="http://www.tei-c.org/ns/1.0"><roleName>M. D</roleName><surname>Mason</surname></persName>
							<affiliation key="aff12">
								<orgName type="institution">Cardiff University</orgName>
								<address>
									<settlement>Cardiff</settlement>
								</address>
							</affiliation>
						</author>
						<author>
							<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">D</forename><surname>Matheson</surname></persName>
							<affiliation key="aff13">
								<orgName type="department">Faculty of Education Health and Wellbeing</orgName>
								<orgName type="institution">University of Wolverhampton</orgName>
								<address>
									<settlement>Wolverhampton</settlement>
								</address>
							</affiliation>
						</author>
						<author>
							<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">R</forename><surname>Millman</surname></persName>
							<affiliation key="aff2">
								<orgName type="department">Institute of Clinical Trials and Methodology</orgName>
								<orgName type="laboratory">MRC Clinical Trials Unit at UCL</orgName>
								<orgName type="institution">UCL</orgName>
								<address>
									<settlement>London</settlement>
								</address>
							</affiliation>
						</author>
						<author>
							<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">C</forename><forename type="middle">C</forename><surname>Parker</surname></persName>
							<affiliation key="aff7">
								<orgName type="department">Institute of Cancer Research</orgName>
								<address>
									<settlement>Sutton-London</settlement>
								</address>
							</affiliation>
							<affiliation key="aff14">
								<orgName type="institution">Royal Marsden NHS Foundation Trust</orgName>
								<address>
									<settlement>London</settlement>
								</address>
							</affiliation>
						</author>
						<author>
							<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">A</forename><forename type="middle">W S</forename><surname>Ritchie</surname></persName>
							<affiliation key="aff2">
								<orgName type="department">Institute of Clinical Trials and Methodology</orgName>
								<orgName type="laboratory">MRC Clinical Trials Unit at UCL</orgName>
								<orgName type="institution">UCL</orgName>
								<address>
									<settlement>London</settlement>
								</address>
							</affiliation>
						</author>
						<author>
							<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">H</forename><surname>Rush</surname></persName>
							<affiliation key="aff2">
								<orgName type="department">Institute of Clinical Trials and Methodology</orgName>
								<orgName type="laboratory">MRC Clinical Trials Unit at UCL</orgName>
								<orgName type="institution">UCL</orgName>
								<address>
									<settlement>London</settlement>
								</address>
							</affiliation>
						</author>
						<author>
							<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">J</forename><forename type="middle">M</forename><surname>Russell</surname></persName>
							<affiliation key="aff15">
								<orgName type="department">Institute of Cancer Sciences</orgName>
								<orgName type="institution">Beatson West of Scotland Cancer Centre</orgName>
								<address>
									<settlement>Glasgow</settlement>
								</address>
							</affiliation>
						</author>
						<author>
							<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">J</forename><surname>Brown</surname></persName>
							<affiliation key="aff16">
								<orgName type="institution">University of Sheffield</orgName>
								<address>
									<settlement>Sheffield</settlement>
								</address>
							</affiliation>
						</author>
						<author>
							<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">S</forename><surname>Beesley</surname></persName>
							<affiliation key="aff17">
								<orgName type="department">Kent Oncology Centre</orgName>
								<address>
									<settlement>Maidstone</settlement>
								</address>
							</affiliation>
						</author>
						<author>
							<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">A</forename><surname>Birtle</surname></persName>
							<affiliation key="aff18">
								<orgName type="institution">Lancashire Teaching Hospitals NHS Foundation Trust</orgName>
								<address>
									<settlement>Preston</settlement>
								</address>
							</affiliation>
						</author>
						<author>
							<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">L</forename><surname>Capaldi</surname></persName>
							<affiliation key="aff19">
								<orgName type="institution">Worcestershire Acute Hospitals NHS Trust</orgName>
								<address>
									<settlement>Worcester</settlement>
								</address>
							</affiliation>
						</author>
						<author>
							<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">J</forename><surname>Gale</surname></persName>
							<affiliation key="aff20">
								<orgName type="department">Portsmouth Oncology Centre</orgName>
								<orgName type="institution">Queen Alexandra Hospital</orgName>
								<address>
									<settlement>Portsmouth</settlement>
								</address>
							</affiliation>
						</author>
						<author>
							<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">S</forename><surname>Gibbs</surname></persName>
							<affiliation key="aff21">
								<orgName type="institution">Queen&apos;s Hospital</orgName>
								<address>
									<settlement>Romford</settlement>
								</address>
							</affiliation>
						</author>
						<author>
							<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">A</forename><surname>Lydon</surname></persName>
							<affiliation key="aff22">
								<orgName type="institution">Torbay and South Devon NHS Foundation Trust</orgName>
								<address>
									<settlement>Torbay</settlement>
								</address>
							</affiliation>
						</author>
						<author>
							<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">A</forename><surname>Nikapota</surname></persName>
							<affiliation key="aff23">
								<orgName type="institution">Sussex Cancer Centre</orgName>
								<address>
									<settlement>Brighton</settlement>
								</address>
							</affiliation>
						</author>
						<author>
							<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">A</forename><surname>Omlin</surname></persName>
							<affiliation key="aff24">
								<orgName type="department">Department of Oncology and Haematology</orgName>
								<address>
									<settlement>Kantonsspital, St Gallen</settlement>
									<country key="CH">Switzerland</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">J</forename><forename type="middle">M</forename><surname>O'sullivan</surname></persName>
							<affiliation key="aff25">
								<orgName type="laboratory">Centre for Cancer Research and Cell Biology</orgName>
								<orgName type="institution">Queen&apos;s University Belfast</orgName>
								<address>
									<settlement>Belfast</settlement>
								</address>
							</affiliation>
						</author>
						<author>
							<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">O</forename><surname>Parikh</surname></persName>
							<affiliation key="aff26">
								<orgName type="institution">East Lancashire Hospitals NHS Trust</orgName>
								<address>
									<settlement>Blackburn</settlement>
								</address>
							</affiliation>
						</author>
						<author>
							<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">A</forename><surname>Protheroe</surname></persName>
							<affiliation key="aff27">
								<orgName type="institution">Oxford University Hospitals NHS Foundation Trust</orgName>
								<address>
									<settlement>Oxford</settlement>
								</address>
							</affiliation>
						</author>
						<author>
							<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">S</forename><surname>Rudman</surname></persName>
							<affiliation key="aff5">
								<orgName type="laboratory">Guy&apos;s and Saint Thomas&apos; NHS Foundation Trust</orgName>
								<address>
									<settlement>London</settlement>
								</address>
							</affiliation>
						</author>
						<author>
							<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">N</forename><forename type="middle">N</forename><surname>Srihari</surname></persName>
							<affiliation key="aff28">
								<orgName type="institution">Shrewsbury and Telford Hospital NHS Trust</orgName>
								<address>
									<settlement>Shrewsbury</settlement>
								</address>
							</affiliation>
						</author>
						<author>
							<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">M</forename><surname>Simms</surname></persName>
							<affiliation key="aff29">
								<orgName type="institution">Hull and East Yorkshire Hospitals NHS Trust</orgName>
								<address>
									<settlement>Hull</settlement>
								</address>
							</affiliation>
						</author>
						<author>
							<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">J</forename><forename type="middle">S</forename><surname>Tanguay</surname></persName>
							<affiliation key="aff30">
								<orgName type="institution">Velindre Cancer Centre</orgName>
								<address>
									<settlement>Cardiff</settlement>
								</address>
							</affiliation>
						</author>
						<author>
							<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">S</forename><surname>Tolan</surname></persName>
							<affiliation key="aff11">
								<orgName type="institution">The Clatterbridge Cancer Centre NHS Foundation Trust</orgName>
								<address>
									<settlement>Liverpool</settlement>
								</address>
							</affiliation>
						</author>
						<author>
							<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">J</forename><surname>Wagstaff</surname></persName>
							<affiliation key="aff31">
								<orgName type="institution">Swansea University College of Medicine</orgName>
								<address>
									<settlement>Swansea</settlement>
								</address>
							</affiliation>
						</author>
						<author>
							<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">J</forename><surname>Wallace</surname></persName>
							<affiliation key="aff10">
								<orgName type="institution" key="instit1">Beatson West of Scotland Cancer Centre</orgName>
								<orgName type="institution" key="instit2">University of Glasgow</orgName>
								<address>
									<settlement>Glasgow</settlement>
								</address>
							</affiliation>
						</author>
						<author>
							<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">J</forename><surname>Wylie</surname></persName>
							<affiliation key="aff32">
								<orgName type="institution">The Christie NHS Foundation Trust</orgName>
								<address>
									<settlement>Manchester</settlement>
								</address>
							</affiliation>
						</author>
						<author>
							<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">A</forename><surname>Zarkar</surname></persName>
							<affiliation key="aff33">
								<orgName type="institution">Heartlands Hospital</orgName>
								<address>
									<settlement>Birmingham</settlement>
								</address>
							</affiliation>
						</author>
						<author>
							<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">M</forename><forename type="middle">R</forename><surname>Sydes</surname></persName>
							<affiliation key="aff2">
								<orgName type="department">Institute of Clinical Trials and Methodology</orgName>
								<orgName type="laboratory">MRC Clinical Trials Unit at UCL</orgName>
								<orgName type="institution">UCL</orgName>
								<address>
									<settlement>London</settlement>
								</address>
							</affiliation>
						</author>
						<author>
							<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">M</forename><forename type="middle">K B</forename><surname>Parmar</surname></persName>
							<affiliation key="aff2">
								<orgName type="department">Institute of Clinical Trials and Methodology</orgName>
								<orgName type="laboratory">MRC Clinical Trials Unit at UCL</orgName>
								<orgName type="institution">UCL</orgName>
								<address>
									<settlement>London</settlement>
								</address>
							</affiliation>
						</author>
						<author>
							<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">N</forename><forename type="middle">D</forename><surname>James</surname></persName>
						</author>
						<author>
							<persName xmlns="http://www.tei-c.org/ns/1.0"><roleName>Prof</roleName><forename type="first">W</forename><surname>Noel</surname></persName>
						</author>
						<author>
							<persName xmlns="http://www.tei-c.org/ns/1.0"><surname>Clarke</surname></persName>
						</author>
						<author>
							<affiliation key="aff34">
								<orgName type="department">Institute of Cancer and Genomic Sciences</orgName>
								<orgName type="institution">University of Birmingham</orgName>
								<address>
									<settlement>Birmingham</settlement>
								</address>
							</affiliation>
						</author>
						<author>
							<affiliation key="aff35">
								<orgName type="department">The Christie NHS Foundation Trust</orgName>
								<address>
									<addrLine>Wilmslow Road</addrLine>
									<postCode>M20 4BX</postCode>
									<settlement>Manchester</settlement>
									<country key="GB">UK</country>
								</address>
							</affiliation>
						</author>
						<author>
							<affiliation key="aff36">
								<address>
									<addrLine>Medivation, Abbott Laboratories, Essa Pharmaceuticals, Bayer Healthcare Pharmaceuticals</addrLine>
									<settlement>Janssen, Roche/Ventana</settlement>
								</address>
							</affiliation>
						</author>
						<title level="a" type="main">Addition of docetaxel to hormonal therapy in low-and high-burden metastatic hormone sensitive prostate cancer: long-term survival results from the STAMPEDE trial</title>
					</analytic>
					<monogr>
						<imprint>
							<date type="published" when="2019-09-27">27 September 2019</date>
						</imprint>
					</monogr>
					<idno type="DOI">10.1093/annonc/mdz396</idno>
					<note type="submission">and Pfizer, outside the submitted work; personal fees from Novartis, Millennium Pharmaceuticals, Takeda, Veridex and the Institute of Cancer Research (ICR), outside the submitted work; grants from AstraZeneca, Arno Therapeutics, Innocrin Pharma and Veridex, outside the submitted work; received a share of this income through the ICR&apos;s Rewards to Discoverers Scheme. SC reports personal fees from Janssen Pharmaceutical, outside the submitted work. WC reports personal fees from Janssen and other from Bayer outside the submitted work. DPD reports other from UK</note>
				</biblStruct>
			</sourceDesc>
		</fileDesc>
		<encodingDesc>
			<appInfo>
				<application version="0.6.1" ident="GROBID" when="2020-10-09T18:38+0000">
					<desc>GROBID - A machine learning software for extracting information from scholarly documents</desc>
					<ref target="https://github.com/kermitt2/grobid"/>
				</application>
			</appInfo>
		</encodingDesc>
		<profileDesc>
			<textClass>
				<keywords>
					<term>prostate cancer</term>
					<term>metastatic</term>
					<term>hormone naive</term>
					<term>docetaxel</term>
					<term>STAMPEDE trial</term>
					<term>randomised control trial</term>
				</keywords>
			</textClass>
			<abstract>
				<p>Background: STAMPEDE has previously reported that the use of upfront docetaxel improved overall survival (OS) for metastatic hormone naïve prostate cancer patients starting long-term androgen deprivation therapy. We report on long-term outcomes stratified by metastatic burden for M1 patients. Methods: We randomly allocated patients in 2 : 1 ratio to standard-of-care (SOC; control group) or SOC þ docetaxel. Metastatic disease burden was categorised using retrospectively-collected baseline staging scans where available. Analysis used Cox regression models, adjusted for stratification factors, with emphasis on restricted mean survival time where hazards were non-proportional.</p>
			</abstract>
		</profileDesc>
	</teiHeader>
	<text xml:lang="en">
		<body>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Introduction</head><p>The primary analysis of STAMPEDE's 'docetaxel comparison', reporting an improvement in survival, was triggered by reaching a pre-specified number of control group deaths <ref type="bibr" target="#b0">[1]</ref>. The trial team agreed to update this analysis when there was a meaningful increase in the number of primary outcome measure events after further follow-up, expected to occur $3 years later. During that time, the Intermediate Clinical Endpoints in Cancer of the Prostate surrogacy work showed that measures based on metastatic progression could be used as a surrogate for survival in patients presenting with M0 disease, allowing trials in that setting to achieve increased power sooner <ref type="bibr" target="#b1">[2]</ref>. Given the prognosis for metastatic and non-metastatic patients is now very different and that other trials of first-line docetaxel have kept metastatic and non-metastatic patients separate, the STAMPEDE team agreed that the long-term follow-up results would be analysed separately for these two groups of patients.</p><p>Since that initial STAMPEDE report, first-line systemic combination treatment options given with ADT in metastatic hormone naïve prostate cancer (mHNPC) have expanded to include abiraterone, enzalutamide and apalutamide as well as docetaxel <ref type="bibr" target="#b0">[1,</ref><ref type="bibr" target="#b2">[3]</ref><ref type="bibr" target="#b3">[4]</ref><ref type="bibr" target="#b4">[5]</ref><ref type="bibr" target="#b5">[6]</ref><ref type="bibr" target="#b6">[7]</ref><ref type="bibr" target="#b7">[8]</ref>. However there is still controversy about patient stratification and selection for treatment. Metastatic burden sub-group analyses of the CHAARTED and GETUG-15 trials have led some to conclude that docetaxel should not be given as a first-line treatment of patients presenting with 'low metastatic burden' disease <ref type="bibr" target="#b2">[3,</ref><ref type="bibr" target="#b8">[9]</ref><ref type="bibr" target="#b9">[10]</ref><ref type="bibr" target="#b10">[11]</ref>. This represents $40% of patients presenting with de novo mHNPC <ref type="bibr" target="#b11">[12,</ref><ref type="bibr" target="#b12">13]</ref>. These were retrospective analyses of relatively small subgroups of these trials and a number of groups have not been persuaded by these exploratory retrospective analyses. Reflecting this uncertainty, major treatment guidelines offer conflicting advice about whether all metastatic patients should receive combination treatment or whether this should be restricted only to those with 'high-burden', as specified in the CHAARTED trial <ref type="bibr" target="#b10">[11,</ref><ref type="bibr" target="#b13">[14]</ref><ref type="bibr" target="#b14">[15]</ref><ref type="bibr" target="#b15">[16]</ref>.</p><p>To address the hypothesis raised by CHAARTED, bone scans from the M1 docetaxel comparison cohort were collected retrospectively to determine the metastatic burden for STAMPEDE patients (independently of treatment assignment and outcome) and to undertake a stratified sub-group analysis. Outcome for the sub-groups categorised by individual metastatic burden was then determined using the extended patient follow-up now available in the STAMPEDE M1 cohort.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Materials and methods</head></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Study design</head><p>The multi-arm, multi-stage STAMPEDE trial enrols patients with advanced high-risk or metastatic prostate cancer. Between 05 October 2005 and 31 March 2013, men with newly diagnosed metastatic prostate cancer were randomised on a 2 : 1 basis either to a standard-of-care (SOC) control group ('Control') or SOC þ docetaxel treatment group ('docetaxel') <ref type="bibr" target="#b0">[1]</ref>. SOC in M1 patients comprised long-term androgen deprivation therapy (ADT), the intervention being lifelong ADT and six cycles of docetaxel at standard dose. Randomisation followed a minimisation algorithm with a random element of 20%, stratified for hospital site, age at randomisation (&lt;70 years old versus !70 years old at randomisation), WHO performance status (a score of 0 versus 1/2), nodal involvement (negative, positive or unspecified), planned ADT and usage (yes/no) of aspirin or other non-steroidal anti-inflammatory drugs (NSAIDs). The randomisation algorithm was developed and maintained centrally at the MRC Clinical Trials Unit at UCL. The trial was carried out in accordance with Good Clinical Practice guidelines, with full regulatory and ethical approval.</p><p>The first efficacy results for docetaxel within the STAMPEDE <ref type="bibr" target="#b0">[1]</ref> used data from the initial randomisation in October 2005 to the data freeze with follow-up to March 2015. The date of this analysis was predetermined by accumulation of events in the control group. In this paper, we report on a pre-planned long-term efficacy analyses of the M1 patient cohort but with updated results using extended follow-up data to July 2018.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Procedures</head><p>All procedures relating to administration and reporting of docetaxel as a research treatment have been reported previously <ref type="bibr" target="#b0">[1]</ref>. In brief, patients were randomised to lifelong ADT with or without six cycles of docetaxel (75 mg/m 2 ) given 3-weekly with prednisolone 5 mg twice daily during the 18-week period of therapy.</p><p>The follow-up schedule, defined in the trial protocol, involved followup visits every 6 weeks until 6 months after randomisation, then 12 weeks to 2 years, 6 months to 5 years and annually thereafter. Toxicity was reported routinely at follow-up visits. Adverse event classification and grades followed the National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) version 4.0. Since the primary report for this comparison, data on baseline metastatic burden has been retrospectively collected where possible for UK patients blinded to treatment outcomes. Metastatic burden was assessed using whole-body scintigraphy and computed tomography or magnetic resonance imaging staging scans, categorised following the definition used in the CHAARTED trial <ref type="bibr" target="#b2">[3]</ref>, where high-burden patients had either four or more bone metastases including one or more outside the vertebral body or pelvis, or any visceral metastases, or both. All other patients metastatic at baseline were categorised as having low metastatic burden according to this definition.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Outcomes</head><p>Overall survival was specified as the primary efficacy outcome and defined as time from randomisation to death from any cause. Secondary outcomes for long-term efficacy data included: failure-free survival (FFS; time from randomisation to the first of any: biochemical, lymph node, distant metastatic progression or prostate cancer death); progressionfree survival (PFS; time from randomisation to the first FFS event, not including biochemical progression); metastatic progression-free survival (mPFS; time from randomisation to either new metastases, progression of existing metastases or prostate cancer death) and prostate cancerspecific survival (PCSS; time from randomisation to prostate cancer death). Biochemical progression was assessed using prostate-specific antigen (PSA) measurements which were reported at each follow-up visit. The lowest PSA value within the first 24 weeks after enrolment was used to define a nadir, from which an increase of 50% and to a minimum level of 4 ng/ml indicated biochemical progression. For a small proportion of patients, PSA levels did not fall after enrolment and a nadir could not be estimated; these patients were considered to have biochemical progression at the date of randomisation. Patients without any event of interest reported by the time of the data freeze were censored in the analyses at the time they were last recorded in the trial as without an event.</p><p>The cause of death was assigned as prostate cancer/not prostate cancer where possible, using a set of rules pre-specified by the Trial Management Group's End point Review Committee. Any deaths not meeting the prespecified rules were individually reviewed by a trial clinician to assign a cause of death independent of the allocated treatment.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Statistical analysis</head><p>Sample size calculations for trial design used the nstage function in Stata, based on a target HR of 0.75 for the primary efficacy analysis. Long-term outcome analysis was planned for $3 years after the first analysis, when there was projected to be a 40% increase in control group deaths. For the long-term analysis by metastatic disease burden, there was 66% and 77% power to detect a hazard ratio of 0.75 in the low and high-burden sub-groups, respectively. This calculation used the observed accrual and previous event rate in the control group (without reference to any accumulating differences between arms/sub-groups).</p><p>Efficacy analyses, following intention-to-treat principles, included all patients allocated to a trial arm. Toxicity and adverse event data are presented with patients grouped according to whether or not docetaxel treatment was reported as having been started (29 patients randomised to docetaxel who did not receive the drug are reported as Controls for the purposes of comparing toxicity between the treatments). See <ref type="figure" target="#fig_0">Figure 1</ref> for full details of patients included in the analyses.</p><p>All time-to-event analyses followed standard survival analysis methods using Stata (version 15.1). Median duration of follow-up period was estimated using the Kaplan-Meier method with reverse-censoring of any reported deaths. Hazard ratios were estimated from Cox proportional hazards regression models, adjusted for minimisation factors used in the randomisation algorithm (nodal stage, age at randomisation, WHO performance score, use of aspirin/NSAIDs, planned use of SOC radiotherapy) and stratified by time period, as defined according to the other arms open to accrual in STAMPEDE (i.e. changes through closure or opening of other trial arms on the platform) or SOC practice changes. Nonparametric stratified log-rank tests were used to test for differences between the control and docetaxel groups, with stratification the same as that of the Cox regression models. Flexible parametric models were used to generate 5-year survival estimates, fitted using (5,5) degrees of freedom with adjustment variables as specified above. PCSS was analysed using Fine and Grey regression methods for competing risks analysis <ref type="bibr" target="#b16">[17]</ref>. For all outcomes, models were tested for evidence of non-proportional hazards, and where found, interpretation of the results emphasises restricted mean survival time (RMST), which was calculated using a t* of 120 months, estimated as described previously <ref type="bibr" target="#b17">[18]</ref>. For all statistical tests, two-sided tests were used and 95% confidence intervals and P-values are reported. Sub-group analyses are presented for all outcomes for metastatic burden sub-groups (low-and high-burden sub-groups). Although our emphasis is on metastatic burden, exploratory sub-group analyses are also presented for the primary outcome in order to give detail on the consistency of treatment effect across baseline factors of potential interest for this patient population: nodal status (N0, Nþ or NX), Gleason sum score ( 7, 8-10 or unknown), patient age (&lt;70 or !70) and WHO performance score (0 or 1-2).</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Results</head><p>One thousand and eighty-six metastatic patients (724 control/ 362 docetaxel) were recruited to STAMPEDE's 'docetaxel comparison' between 05 October 2005 and 31 March 2013. The dataset for this analysis was frozen on 13 July 2018. As reported previously, baseline patient characteristics were well-balanced across trial arms <ref type="table" target="#tab_1">(Table 1)</ref>. We additionally report sub-group analyses according to metastatic burden, which was assessed using bone scans available from 830/1086 (76%) of all recruited patients. The patients included in these sub-group analyses were well-balanced across arms <ref type="table" target="#tab_1">(Table 2 and supplementary Table S1</ref>, available at Annals of Oncology online). In addition, a comparison of <ref type="table" target="#tab_1">Tables 1 and 2</ref> demonstrates that the subset of patients included in the metastatic burden sub-group analyses was representative of the metastatic patients in the comparison as a whole, with the exception of the year of randomisation, where the patients included in the metastatic burden sub-group analyses were enrolled in the latter years of recruitment to the comparison. <ref type="figure" target="#fig_0">Figure 1</ref> shows a Consort diagram with full details of patient numbers included in the analyses.</p><p>The median duration of follow-up was 78.2 months (interquartile range (IQR): 62.9-96.3). There were 719 deaths reported; 494/724 (68%) control patients died compared with 225/362 (62%) docetaxel patients. Control group patients had a median survival of 43.1 months and an estimated 5-year survival of 37% (95% CI 34% to 41%), whereas patients receiving docetaxel had a median survival of 59.1 months and 5-year survival of 49% (95% CI 44% to 54%). There was good evidence of a benefit from docetaxel on survival (stratified log-rank test P ¼ 0.003, HR ¼ 0.81, 95% CI 0.69-0.95; <ref type="figure" target="#fig_5">Figure 2A</ref>). As there was evidence (P ¼ 0.016) of non-proportional hazards in the treatment effect, the interpretation of these results focuses on the difference in RMST between arms. This method showed evidence of a benefit of docetaxel, with an estimated difference of 6.0 months (95% CI 0.7-11.4) in RMST (over 120 months) between groups.</p><p>There was no evidence of heterogeneity of treatment effect on survival over metastatic burden sub-groups (interaction P ¼ 0.827). For the low-burden patients (n ¼ 362, deaths ¼ 166; <ref type="figure" target="#fig_5">Figure 2C</ref>), the median survival in control was 76.7 months, with 5-year survival 57% (95% CI 51% to 64%), compared with a median of 93.2 months and 5-year survival of 72% (95% CI 65% to 80%) for docetaxel. Results for high-burden patients (n ¼ 468, deaths ¼ 360) were similar in terms of docetaxel effect, although, as expected, the high-burden patients generally had shorter survival time than low-burden patients <ref type="figure" target="#fig_5">(Figure 2E</ref>). The median survival for control was 35.2 months and the 5-year survival estimate of 24% (95% CI 20% to 29%), compared with 39.9 months with a 5-year survival of 34% (95% CI 27% to 42%) for docetaxel. The hazard ratios were consistent in the low-burden (HR ¼ 0.76, 95% CI 0.54-1.07, P ¼ 0.107) and high-burden (HR ¼ 0.81, 95% CI 0.64-1.02, P ¼ 0.064) sub-groups. The consistency of docetaxel treatment effect on survival across other baseline characteristics was examined as exploratory sub-group analyses, summarised in <ref type="figure">Figure 3</ref>. There is no good evidence that the docetaxel effect varies across any of the sub-groups included (nodal status, Gleason sum score, age or WHO performance score).</p><p>There was good evidence of significant benefit for adding docetaxel on failure-free (HR ¼ 0.66, 95% CI 0.57-0.76, P &lt; 0.001; <ref type="figure" target="#fig_5">Figure 2B</ref>), progression-free (HR ¼ 0.69, 95% CI 0.59-0.81, P &lt; 0.001; <ref type="figure" target="#fig_6">Figure 4A</ref>), metastatic progression-free (HR ¼ 0.72, 95% CI 0.62-0.84, P &lt; 0.001; <ref type="figure" target="#fig_6">Figure 4B</ref>) and PCSS (sub-HR ¼ 0.78, 95% CI 0.66-0.93, P ¼ 0.005; <ref type="figure" target="#fig_6">Figure 4C</ref>). Furthermore, the effect of treatment was consistent across metastatic burden sub-groups (interaction P-values: FFS ¼ 0.792; PFS ¼ 0.855; mPFS ¼ 0.960; PCSS ¼ 0.413) for other outcome measures <ref type="table">(Table 3)</ref>.</p><p>Treatment adherence to docetaxel was reported previously <ref type="bibr" target="#b0">[1]</ref>; all patients had completed docetaxel treatment before the first efficacy analysis. Twenty-nine metastatic patients allocated to Docetaxel never reported starting chemotherapy. They are included in Control for toxicity analysis (see <ref type="figure" target="#fig_0">Figure 1</ref>) which is summarised in <ref type="table" target="#tab_2">Table 4 and supplementary Table S2</ref> and <ref type="figure" target="#fig_0">Figure  S1</ref>, available at Annals of Oncology online. A comparison of toxicity reported across groups in the first year of follow-up shows higher toxicity in docetaxel (42% docetaxel reported G3-5 toxicity versus 24% in Control). However, toxicity reports for subsequent follow-up, after the initial year, are balanced across groups (27% docetaxel reported G3-5 toxicity compared with 28%  control), with no good evidence of increased toxicity in the docetaxel group after the first year of follow-up. <ref type="table">Table 5</ref> shows some evidence that control patients were more likely to report starting second-line (or subsequent) treatment following disease progression, with 80% reporting starting at least one further line of treatment compared with 68% for Docetaxel. The types of further therapy reported are broadly similar between the two groups.</p><p>A sensitivity analysis was undertaken without the M1 patients retrospectively found not to have met all of the strict protocol eligibility criteria, mostly concerning a review of baseline blood pressure measurements. Removing these 120 patients (11%) did not change the primary outcome measure results HR ¼ 0.81 (95% CI 0.68-0.96; P ¼ 0.013).</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Discussion</head><p>In this updated long-term analysis, the relative survival benefit for adding docetaxel to ADT in mHNPC confirmed our previous findings. A statistically and clinically significant improvement in survival and a delayed time to metastatic progression was demonstrated with the combination treatment compared with ADT alone. Importantly, this benefit is seen irrespective of metastatic burden, with no evidence of heterogeneity between the low and high metastatic burden sub-groups across any outcome measures. This reinforces the principle that ADT and docetaxel can be considered as an effective first-line treatment option for men with mHNPC regardless of metastatic burden.</p><p>Two other trials have also evaluated the combination of docetaxel with ADT over ADT alone in mHNPC. The first trial, GETUG-AFU-15, enrolled 385 patients and reported with median follow-up of 84 months. This showed no clear evidence of improvement in survival by adding docetaxel to ADT over ADT alone (HR ¼ 0.88, 95% CI 0.68-1.14, P ¼ 0.3) <ref type="bibr" target="#b18">[19]</ref>. The second trial, CHAARTED, enrolled 790 patients and reported with median follow-up of 54 months, demonstrating clear evidence of an improvement in survival for adding docetaxel (HR ¼ 0.72, 95% CI 0.59-0.89, P ¼ 0.0018) <ref type="bibr" target="#b2">[3,</ref><ref type="bibr" target="#b8">9]</ref>. STAMPEDE is the largest of the 3 trials, enrolling 1086 mHNPC patients and reporting here with median follow-up of 78 months. Our long-term results for these metastatic patients lie between those of GETUG-AFU-15 and CHAARTED and show clear evidence of improved survival associated with the combination of docetaxel þ ADT over ADT alone (HR ¼ 0.81, 95% CI 0.69-0.95, P ¼ 0.009). However, in contrast to the CHAARTED and GETUG-15 trials, we found no good evidence in this study of a difference in benefit between the high and low metastatic burden sub-groups for survival and all other outcome measures. Indeed, the point estimate of the benefit for 'low-burden' patients was of 'greater' magnitude than that for the high-burden group. Prior sub-group analysis conducted as part of the CHAARTED and GETUG-15 trials suggested a smaller overall survival benefit associated with the combination of docetaxel þ ADT in patients with low metastatic burden compared with high metastatic burden <ref type="bibr" target="#b9">[10]</ref>. Based on this, docetaxel was recommended by those authors as a firstline option only for high but not low-burden mHNPC <ref type="bibr" target="#b10">[11]</ref>. That view was not universally accepted and the inherent limitations of the previous sub-group analyses can possibly explain the discordance to our new findings <ref type="bibr" target="#b13">[14]</ref><ref type="bibr" target="#b14">[15]</ref><ref type="bibr" target="#b15">[16]</ref>. Nearly 25% of the patients enrolled in the other two trials presented with metastatic disease after previous radical treatment. That group of patients has a different natural history to those presenting with de-novo M1 disease <ref type="bibr" target="#b19">[20,</ref><ref type="bibr" target="#b20">21]</ref>. Consequently, the low metastatic burden sub-groups in the CHAARTED and the GETUG-15 trials had fewer than 160 de-novo mHNPC patients each <ref type="bibr" target="#b9">[10]</ref>. In our updated report, $95% of patients had de-novo M1, with a total of 362 patients in the low metastatic burden sub-group. This larger sample size provides a stronger basis for estimating a treatment effect in this sub-group. Furthermore, there was no evidence of a difference in benefit associated with docetaxel with ADT over ADT alone when considering metastatic burden (interaction P ¼ 0.827). Based on these findings, the combination of docetaxel with ADT should be a first-line treatment option for newly diagnosed mHNPC patients regardless of metastatic burden.</p><p>Our results have to be interpreted in light of more recentlyrecruited trials. Since the last report, a number of other systemic  treatments such as abiraterone, apalutamide and enzalutamide have also shown statistically and clinically significant survival benefits over SOC alone when used as first-line agents in mHNPC <ref type="bibr" target="#b3">[4]</ref><ref type="bibr" target="#b4">[5]</ref><ref type="bibr" target="#b5">[6]</ref><ref type="bibr" target="#b6">[7]</ref>. None of the trials using androgen receptor pathway targeting have shown any evidence of heterogeneity of effect by metastatic burden. Our previous analysis of patients randomised contemporaneously within STAMPEDE to a docetaxel group or an abiraterone group did not show any difference in overall survival. Whilst that was acknowledged as underpowered, opportunistic comparison, it remains the only direct randomised comparison of docetaxel and abiraterone, and the results are in keeping with both agents being valid first-line options when combined with ADT <ref type="bibr" target="#b21">[22]</ref>.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Conclusion</head><p>This updated report, with long-term follow-up and metastatic burden sub-group analysis, reinforces the benefits of adding docetaxel to ADT in mHNPC. The combination treatment</p><p>Overall survival -all M1</p><p>1.00</p><p>Control Docetaxel</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Control Docetaxel</head><p>Control Docetaxel</p><p>Control Docetaxel </p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Control</head><p>(3)</p><p>(0)  </p><p>(1) Time since randomisation (years)    </p></div><figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_0"><head>Figure 1 .</head><label>1</label><figDesc>Consort diagram.</figDesc></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_5"><head>Figure 2 .</head><label>2</label><figDesc>low-burden M1 Overall survival -high-burden M1 Failure-free survival -all M1 Failure-free survival -low-burden M1 Overall survival -high-burden M1 Kaplan-Meier curves (solid line) and fitted flexible parametric model estimates (dashed line) for overall survival (left) and failurefree survival (right), by trial arm, for all M1 patients (A,B) low-burden M1 patients (C,D) and high-burden M1 patients (E,F). prolongs survival and improves a range of outcome measures, including time to metastatic progression and subsequent therapy. It should be considered as a first-line option for fit patients with mHNPC, irrespective of metastatic burden.</figDesc></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_6"><head>Figure 4 .</head><label>4</label><figDesc>Kaplan-Meier curves (solid line) and fitted flexible parametric model estimates (dashed line), by trial arm, for (A) progression-free survival and (B) metastatic progression-free survival; (C) shows the cumulative incidence function, by trial arm, for prostate cancer death (solid line) and non-prostate cancer death (dashed line).</figDesc></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_1"><head>Table 1 .</head><label>1</label><figDesc>Baseline characteristics for all metastatic patients, by trial arm Patients may have had more than one site of metastases at baseline, therefore are represented in more than one 'site of metastases' category. Percentages shown are per individual site for the total patients in the arm.</figDesc><table><row><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>Table 1. Continued</cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>Patient characteristic</cell><cell>Control</cell><cell></cell><cell cols="2">Docetaxel</cell><cell>Patient characteristic</cell><cell>Control</cell><cell></cell><cell cols="2">Docetaxel</cell></row><row><cell>Randomised (2 : 1 allocation)</cell><cell>724</cell><cell>100%</cell><cell>362</cell><cell>100%</cell><cell>2012</cell><cell>172</cell><cell>24%</cell><cell>85</cell><cell>23%</cell></row><row><cell>Age at randomisation (years)</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>2013</cell><cell>42</cell><cell>6%</cell><cell>19</cell><cell>5%</cell></row><row><cell>Median</cell><cell>65</cell><cell></cell><cell>65</cell><cell></cell><cell>Total</cell><cell>724</cell><cell>100%</cell><cell>362</cell><cell>100%</cell></row><row><cell>IQR</cell><cell cols="2">60-71</cell><cell cols="2">60-70</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>WHO performance status</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>0</cell><cell>521</cell><cell>72%</cell><cell>270</cell><cell>75%</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>1-2</cell><cell>203</cell><cell>28%</cell><cell>92</cell><cell>25%</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>T stage</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>T0</cell><cell>3</cell><cell>&lt;1%</cell><cell>1</cell><cell>&lt;1%</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>T1</cell><cell>12</cell><cell>2%</cell><cell>0</cell><cell>0%</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>T2</cell><cell>75</cell><cell>10%</cell><cell>51</cell><cell>14%</cell><cell cols="5">Primary site RT was not standard-of-care (SOC) for M1 patients at the</cell></row><row><cell>T3</cell><cell>404</cell><cell>56%</cell><cell>197</cell><cell>54%</cell><cell cols="5">time of the trial. However, SOC RT was reported as planned for a small</cell></row><row><cell>T4</cell><cell>163</cell><cell>23%</cell><cell>82</cell><cell>23%</cell><cell cols="5">proportion of patients due to clinical decisions for these individual cases</cell></row><row><cell>TX</cell><cell>67</cell><cell>9%</cell><cell>31</cell><cell>9%</cell><cell cols="5">to receive RT to non-prostate locations, or due to mis-reporting of pallia-</cell></row><row><cell>Nodal status</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>tive RT.</cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>N0</cell><cell>242</cell><cell>33%</cell><cell>118</cell><cell>33%</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>Nþ</cell><cell>416</cell><cell>57%</cell><cell>211</cell><cell>58%</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>NX</cell><cell>66</cell><cell>9%</cell><cell>33</cell><cell>9%</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>Metastatic burden a</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>Low</cell><cell>238</cell><cell>33%</cell><cell>124</cell><cell>34%</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>High</cell><cell>320</cell><cell>44%</cell><cell>148</cell><cell>41%</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>Unassessed</cell><cell>166</cell><cell>23%</cell><cell>90</cell><cell>25%</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>Site of metastases b</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>Bone</cell><cell>634</cell><cell>88%</cell><cell>307</cell><cell>85%</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>Liver</cell><cell>15</cell><cell>2%</cell><cell>6</cell><cell>2%</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>Lung</cell><cell>33</cell><cell>5%</cell><cell>13</cell><cell>4%</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>Nodes c</cell><cell>221</cell><cell>31%</cell><cell>102</cell><cell>28%</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>Other</cell><cell>46</cell><cell>6%</cell><cell>25</cell><cell>7%</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>Gleason sum score</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>7</cell><cell>158</cell><cell>22%</cell><cell>65</cell><cell>18%</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>8-10</cell><cell>480</cell><cell>66%</cell><cell>253</cell><cell>70%</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>Unknown</cell><cell>86</cell><cell>12%</cell><cell>44</cell><cell>12%</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>PSA</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>Median</cell><cell cols="2">102.5</cell><cell>97</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>IQR</cell><cell cols="2">32.8-354</cell><cell cols="2">40.5-340</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell cols="2">Time from diagnosis to randomisation (days)</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>Median</cell><cell>69</cell><cell></cell><cell>73</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>IQR</cell><cell cols="2">49-92</cell><cell cols="2">55-95</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>Planned SOC RT d</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>Not planned</cell><cell>677</cell><cell>94%</cell><cell>333</cell><cell>92%</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>Planned</cell><cell>47</cell><cell>6%</cell><cell>29</cell><cell>8%</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>Previously treated</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>No</cell><cell>689</cell><cell>95%</cell><cell>347</cell><cell>96%</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>Yes</cell><cell>35</cell><cell>5%</cell><cell>15</cell><cell>4%</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>Pain from prostate cancer</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>Absent</cell><cell>553</cell><cell>76%</cell><cell>270</cell><cell>75%</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>Present</cell><cell>154</cell><cell>21%</cell><cell>88</cell><cell>24%</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>Unknown</cell><cell>17</cell><cell>2%</cell><cell>4</cell><cell>1%</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>Year of randomisation</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>2005</cell><cell>1</cell><cell>&lt;1%</cell><cell>1</cell><cell>&lt;1%</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>2006</cell><cell>28</cell><cell>4%</cell><cell>14</cell><cell>4%</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>2007</cell><cell>38</cell><cell>5%</cell><cell>19</cell><cell>5%</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>2008</cell><cell>70</cell><cell>10%</cell><cell>34</cell><cell>9%</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>2009</cell><cell>93</cell><cell>13%</cell><cell>45</cell><cell>12%</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>2010</cell><cell>111</cell><cell>15%</cell><cell>58</cell><cell>16%</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>2011</cell><cell>169</cell><cell>23%</cell><cell>87</cell><cell>24%</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell></cell><cell></cell><cell></cell><cell cols="2">Continued</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row></table><note>a CHAARTED definition.bc Non-regional lymph nodes.d</note></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_2"><head>Table 2 .</head><label>2</label><figDesc>Baseline characteristics, for the subset of 830/1086 patients included in metastatic burden sub-group analysis, by trial arm</figDesc><table><row><cell>Patient characteristic</cell><cell>Control</cell><cell></cell><cell>Docetaxel</cell><cell></cell></row><row><cell>Randomised</cell><cell>558</cell><cell>100%</cell><cell>272</cell><cell>100%</cell></row><row><cell>Age at randomisation (years)</cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>Median</cell><cell>65</cell><cell></cell><cell>65</cell><cell></cell></row><row><cell>IQR</cell><cell cols="2">60-71</cell><cell cols="2">62-70</cell></row><row><cell>WHO performance status</cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>0</cell><cell>405</cell><cell>73%</cell><cell>204</cell><cell>75%</cell></row><row><cell>1-2</cell><cell>153</cell><cell>27%</cell><cell>68</cell><cell>25%</cell></row><row><cell>T stage</cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>T0</cell><cell>1</cell><cell>&lt;1%</cell><cell>1</cell><cell>&lt;1%</cell></row><row><cell>T1</cell><cell>9</cell><cell>2%</cell><cell>0</cell><cell>0%</cell></row><row><cell>T2</cell><cell>56</cell><cell>10%</cell><cell>36</cell><cell>13%</cell></row><row><cell>T3</cell><cell>315</cell><cell>56%</cell><cell>155</cell><cell>57%</cell></row><row><cell>T4</cell><cell>129</cell><cell>23%</cell><cell>58</cell><cell>21%</cell></row><row><cell>TX</cell><cell>48</cell><cell>9%</cell><cell>22</cell><cell>8%</cell></row><row><cell>Nodal status</cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>N0</cell><cell>185</cell><cell>33%</cell><cell>88</cell><cell>32%</cell></row><row><cell>Nþ</cell><cell>322</cell><cell>58%</cell><cell>161</cell><cell>59%</cell></row><row><cell>NX</cell><cell>51</cell><cell>9%</cell><cell>23</cell><cell>8%</cell></row><row><cell>Metastatic burden a</cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>Low</cell><cell>238</cell><cell>43%</cell><cell>124</cell><cell>46%</cell></row><row><cell>High</cell><cell>320</cell><cell>57%</cell><cell>148</cell><cell>54%</cell></row><row><cell>Site of metastases b</cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>Bone</cell><cell>485</cell><cell>87%</cell><cell>226</cell><cell>83%</cell></row><row><cell>Liver</cell><cell>12</cell><cell>2%</cell><cell>4</cell><cell>1%</cell></row><row><cell>Lung</cell><cell>22</cell><cell>4%</cell><cell>12</cell><cell>4%</cell></row><row><cell>Nodes c</cell><cell>175</cell><cell>31%</cell><cell>78</cell><cell>29%</cell></row><row><cell>Other</cell><cell>38</cell><cell>7%</cell><cell>20</cell><cell>7%</cell></row><row><cell>Gleason sum score</cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>7</cell><cell>118</cell><cell>21%</cell><cell>51</cell><cell>19%</cell></row><row><cell>8-10</cell><cell>381</cell><cell>68%</cell><cell>188</cell><cell>69%</cell></row><row><cell>Unknown</cell><cell>59</cell><cell>11%</cell><cell>33</cell><cell>12%</cell></row><row><cell>PSA</cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>Median</cell><cell cols="2">102.5</cell><cell>96.8</cell><cell></cell></row><row><cell>IQR</cell><cell cols="2">33-338.7</cell><cell cols="2">37.8-348.1</cell></row><row><cell cols="3">Time from diagnosis to randomisation (days)</cell><cell></cell><cell></cell></row><row><cell>Median</cell><cell>69</cell><cell></cell><cell>74</cell><cell></cell></row><row><cell>IQR</cell><cell cols="2">50-92</cell><cell cols="2">56-95</cell></row><row><cell>Planned SOC RT d</cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>Not planned</cell><cell>523</cell><cell>94%</cell><cell>252</cell><cell>93%</cell></row><row><cell>Planned</cell><cell>35</cell><cell>6%</cell><cell>20</cell><cell>7%</cell></row><row><cell>Previously treated</cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>No</cell><cell>528</cell><cell>95%</cell><cell>261</cell><cell>96%</cell></row><row><cell>Yes</cell><cell>30</cell><cell>5%</cell><cell>11</cell><cell>4%</cell></row><row><cell>Pain from prostate cancer</cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>Absent</cell><cell>427</cell><cell>77%</cell><cell>200</cell><cell>74%</cell></row><row><cell>Present</cell><cell>120</cell><cell>22%</cell><cell>69</cell><cell>25%</cell></row><row><cell>Unknown</cell><cell>11</cell><cell>2%</cell><cell>3</cell><cell>1%</cell></row><row><cell>Year of randomisation</cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>2005</cell><cell>0</cell><cell>0%</cell><cell>0</cell><cell>0%</cell></row><row><cell>2006</cell><cell>0</cell><cell>0%</cell><cell>0</cell><cell>0%</cell></row><row><cell>2007</cell><cell>0</cell><cell>0%</cell><cell>0</cell><cell>0%</cell></row><row><cell>2008</cell><cell>19</cell><cell>3%</cell><cell>8</cell><cell>3%</cell></row><row><cell>2009</cell><cell>82</cell><cell>15%</cell><cell>39</cell><cell>14%</cell></row><row><cell>2010</cell><cell>105</cell><cell>19%</cell><cell>52</cell><cell>19%</cell></row><row><cell>2011</cell><cell>157</cell><cell>28%</cell><cell>78</cell><cell>29%</cell></row><row><cell></cell><cell></cell><cell></cell><cell cols="2">Continued</cell></row></table><note></note></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_3"><head>Table 2 .</head><label>2</label><figDesc>Continued</figDesc><table><row><cell>Patient characteristic</cell><cell>Control</cell><cell></cell><cell>Docetaxel</cell><cell></cell></row><row><cell>2012</cell><cell>157</cell><cell>28%</cell><cell>78</cell><cell>29%</cell></row><row><cell>2013</cell><cell>38</cell><cell>7%</cell><cell>17</cell><cell>6%</cell></row><row><cell>Total</cell><cell>558</cell><cell>100%</cell><cell>272</cell><cell>100%</cell></row><row><cell>a CHAARTED definition.</cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell cols="5">b Patients may have had more than one site of metastases at baseline,</cell></row><row><cell cols="5">therefore are represented in more than one 'site of metastases' category.</cell></row><row><cell cols="5">Percentages shown are per individual site for the total patients in the</cell></row><row><cell>arm.</cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>c Non-regional lymph nodes.</cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell cols="5">d Primary site RT was not standard-of-care (SOC) for M1 patients at the</cell></row><row><cell cols="5">time of the trial. However, SOC RT was reported as planned for a small</cell></row><row><cell cols="5">proportion of patients due to clinical decisions for these individual cases</cell></row><row><cell cols="5">to receive RT to non-prostate locations, or due to mis-reporting of pallia-</cell></row><row><cell>tive RT.</cell><cell></cell><cell></cell><cell></cell><cell></cell></row></table><note></note></figure>
			<note xmlns="http://www.tei-c.org/ns/1.0" place="foot" n="1996">| Clarke et al. Volume 30 | Issue 12 | 2019</note>
			<note xmlns="http://www.tei-c.org/ns/1.0" place="foot" n="1998">| Clarke et al. Volume 30 | Issue 12 | 2019</note>
			<note xmlns="http://www.tei-c.org/ns/1.0" place="foot" n="2000">| Clarke et al. Volume 30 | Issue 12 | 2019</note>
			<note xmlns="http://www.tei-c.org/ns/1.0" place="foot" n="2002">| Clarke et al. Volume 30 | Issue 12 | 2019</note>
		</body>
		<back>

			<div type="acknowledgement">
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Acknowledgements</head><p>With thanks to all of the patients who have participated in the trial and everyone who had supported them. The participating site staff and CTU staff, without whom this trial could not be run, are all listed in the Online Appendix. </p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Annals of Oncology</head></div>
			</div>

			<div type="annex">
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Funding</head><p>This work was supported by Cancer Research UK (CRUK_A12459), Medical Research Council (MRC_MC_ UU_12023/25), Astellas, Clovis Oncology, Janssen, Novartis, Pfizer and Sanofi-Aventis.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Disclosure</head><p>NWC has received fees for consultation and lectureships from Sanofi Aventis, Janssen, Astellas, Pfizer, AstraZeneca, Bayer and Ferring pharmaceuticals. GA reports personal fees from Sanofi, Novartis, Nectar Therapeutics, ProteoMedix, Cell Search, Clovis and Bristol-Myers Squibb, outside the submitted work; personal fees from MaxiVax SA, outside the submitted work. RJJ reports personal fees and non-financial support from Janssen; grants, personal fees and other from Astellas; personal fees and other from Sanofi, Novartis, outside the submitted work. AM reports grants from Cancer Research UK's Clinical Research Committee, Medical Research Council, Novartis, Sanofi-Aventis, Pfizer, Janssen Pharma NV, Astellas and Clovis Oncology, during the conduct of the study. ZM reports personal fees from SANOFI, JAANSEN, Pfizer and Bayer, outside the submitted work. MDM reports personal fees and other from Sanofi; personal fees from Janssen and Bayer, outside the submitted work. CCP reports grants, personal fees and other from Bayer; other from AAA; personal fees from Janssen, outside the submitted work. JB reports personal fees from Novartis BMS, Ipsen, MSD, Daiichi-Sankyo and Sandoz; grants and personal fees from Amgen and Bayer, outside the submitted work. AB reports other from Astellas; personal fees and other from Sanofi and Janssen, during the conduct of the study; other from Bayer and Astra Zeneca, outside the submitted work. AO has an advisory role (compensated, institutional) for Astra Zeneca, Astellas, Bayer, Janssen, Molecular Partners, MSD, Pfizer, Roche and Sanofi Aventis. He has received research support <ref type="table">Table 3</ref>. Hazard ratio (95% CI) from adjusted Cox model, 5-year survival estimates by trial arm from flexible parametric model and restricted mean survival times (RMST) by trial arm, for each outcome measure and each metastatic burden sub-group  2 &lt;1% 1 &lt;1% 1 &lt;1% 0 0% No FU/SAE reported 18 n/a 1 n/a 18 n/a 1 n/a Not on FU after one year n/a n/a n/a n/a 281 n/a 77 n/a Total b 753 100% 333 100% 753 100% 333 100%</p><p>a Timed from randomisation. b Total numbers shown for safety population, where 29 patients allocated to the Docetaxel Group never started Docetaxel treatment and are therefore included in the standard-of-care (SOC) group for safety reporting. Note that 'missing' data refers to patients who did not report AE data after this point (either died or withdrawn from the trial, or not reporting AEs after disease progression as specified in the trial protocol). a Any progression event, including biochemical progression. b Percentages shown are calculated using the total numbers of patients reporting at least one SLT for the relevant trial arm. Patient numbers only include patients confirmed to have progressed. Note that patients reporting more than one type of second-line treatment will be represented in more than once. c Other chemotherapy, excluding Docetaxel and Cabazitaxel, which are shown separately. d Other bisphosphonate, excluding Zoledronic acid, which is shown separately.</p></div>			</div>
			<div type="references">

				<listBibl>

<biblStruct xml:id="b0">
	<analytic>
		<title level="a" type="main">Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trial</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">N</forename><forename type="middle">D</forename><surname>James</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">M</forename><forename type="middle">R</forename><surname>Sydes</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">N</forename><forename type="middle">W</forename><surname>Clarke</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Lancet</title>
		<imprint>
			<biblScope unit="volume">387</biblScope>
			<biblScope unit="page" from="1163" to="1177" />
			<date type="published" when="2016" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b1">
	<analytic>
		<title level="a" type="main">Metastasis-free survival is a strong surrogate of overall survival in localized prostate cancer</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">W</forename><surname>Xie</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">M</forename><forename type="middle">M</forename><surname>Regan</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">M</forename><surname>Buyse</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Clin Oncol</title>
		<imprint>
			<biblScope unit="volume">35</biblScope>
			<biblScope unit="issue">27</biblScope>
			<biblScope unit="page" from="3097" to="3104" />
			<date type="published" when="2017" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b2">
	<analytic>
		<title level="a" type="main">Chemohormonal therapy in metastatic hormone-sensitive prostate cancer</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">C</forename><forename type="middle">J</forename><surname>Sweeney</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Y</forename><forename type="middle">H</forename><surname>Chen</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">M</forename><surname>Carducci</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">N Engl J Med</title>
		<imprint>
			<biblScope unit="volume">373</biblScope>
			<biblScope unit="issue">8</biblScope>
			<biblScope unit="page" from="737" to="746" />
			<date type="published" when="2015" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b3">
	<analytic>
		<title level="a" type="main">Abiraterone acetate plus prednisone in patients with newly diagnosed high-risk metastatic castration-sensitive prostate cancer (LATITUDE): final overall survival analysis of a randomised, double-blind, phase 3 trial</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">K</forename><surname>Fizazi</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">N</forename><surname>Tran</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">L</forename><surname>Fein</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Lancet Oncol</title>
		<imprint>
			<biblScope unit="volume">20</biblScope>
			<biblScope unit="issue">5</biblScope>
			<biblScope unit="page" from="686" to="700" />
			<date type="published" when="2019" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b4">
	<analytic>
		<title level="a" type="main">Apalutamide for metastatic, castration-sensitive prostate cancer</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">K</forename><forename type="middle">N</forename><surname>Chi</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">N</forename><surname>Agarwal</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">A</forename><surname>Bjartell</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">N Engl J Med</title>
		<imprint>
			<biblScope unit="volume">381</biblScope>
			<biblScope unit="issue">1</biblScope>
			<biblScope unit="page" from="13" to="24" />
			<date type="published" when="2019" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b5">
	<analytic>
		<title level="a" type="main">Enzalutamide with standard first-line therapy in metastatic prostate cancer</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">I</forename><forename type="middle">D</forename><surname>Davis</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">A</forename><forename type="middle">J</forename><surname>Martin</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">M</forename><forename type="middle">R</forename><surname>Stockler</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">N Engl J Med</title>
		<imprint>
			<biblScope unit="volume">381</biblScope>
			<biblScope unit="issue">2</biblScope>
			<biblScope unit="page" from="121" to="131" />
			<date type="published" when="2019" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b6">
	<analytic>
		<title level="a" type="main">Abiraterone for prostate cancer not previously treated with hormone therapy</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">N</forename><forename type="middle">D</forename><surname>James</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">J</forename><forename type="middle">S</forename><surname>De Bono</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">M</forename><forename type="middle">R</forename><surname>Spears</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">N Engl J Med</title>
		<imprint>
			<biblScope unit="volume">377</biblScope>
			<biblScope unit="issue">4</biblScope>
			<biblScope unit="page" from="338" to="351" />
			<date type="published" when="2017" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b7">
	<analytic>
		<title level="a" type="main">Addition of docetaxel or bisphosphonates to standard of care in men with localised or metastatic, hormone-sensitive prostate cancer: a systematic review and metaanalyses of aggregate data</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">C</forename><forename type="middle">L</forename><surname>Vale</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">S</forename><surname>Burdett</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Lhm</forename><surname>Rydzewska</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Lancet Oncol</title>
		<imprint>
			<biblScope unit="volume">17</biblScope>
			<biblScope unit="issue">2</biblScope>
			<biblScope unit="page" from="243" to="256" />
			<date type="published" when="2016" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b8">
	<analytic>
		<title level="a" type="main">Chemohormonal therapy in metastatic hormone-sensitive prostate cancer: long-term survival analysis of the randomized phase III E3805 CHAARTED trial</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">C</forename><forename type="middle">E</forename><surname>Kyriakopoulos</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Y</forename><forename type="middle">H</forename><surname>Chen</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">M</forename><forename type="middle">A</forename><surname>Carducci</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Clin Oncol</title>
		<imprint>
			<biblScope unit="volume">36</biblScope>
			<biblScope unit="issue">11</biblScope>
			<biblScope unit="page" from="1080" to="1087" />
			<date type="published" when="2018" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b9">
	<analytic>
		<title level="a" type="main">Burden of metastatic castrate naive prostate cancer patients, to identify men more likely to benefit from early docetaxel: further analyses of CHAARTED and GETUG-AFU15 studies</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">G</forename><surname>Gravis</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">J</forename><forename type="middle">M</forename><surname>Boher</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Y</forename><forename type="middle">H</forename><surname>Chen</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Eur Urol</title>
		<imprint>
			<biblScope unit="volume">73</biblScope>
			<biblScope unit="issue">6</biblScope>
			<biblScope unit="page" from="847" to="855" />
			<date type="published" when="2018" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b10">
	<monogr>
		<title level="m" type="main">Network Clinical Practice Guidelines in Oncology-Prostate cancer Version 4</title>
		<ptr target="https://www.nccn.org/professionals/physician_gls/pdf/prostate.pdf" />
		<imprint>
			<date type="published" when="2019-09-15" />
		</imprint>
		<respStmt>
			<orgName>National Comprehensive Cancer</orgName>
		</respStmt>
	</monogr>
	<note>date last accessed</note>
</biblStruct>

<biblStruct xml:id="b11">
	<analytic>
		<title level="a" type="main">Abiraterone in &quot;high-&quot; and &quot;low-risk&quot; metastatic hormone-sensitive prostate cancer</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">A</forename><forename type="middle">P</forename><surname>Hoyle</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">A</forename><surname>Ali</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">N</forename><forename type="middle">D</forename><surname>James</surname></persName>
		</author>
		<idno type="DOI">10.1016/j.eururo.2019.08.006</idno>
	</analytic>
	<monogr>
		<title level="j">Eur Urol</title>
		<imprint>
			<date type="published" when="2019" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b12">
	<analytic>
		<title level="a" type="main">Radiotherapy to the primary tumour for newly diagnosed, metastatic prostate cancer (STAMPEDE): a randomised controlled phase 3 trial</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">C</forename><forename type="middle">C</forename><surname>Parker</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">N</forename><forename type="middle">D</forename><surname>James</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">C</forename><forename type="middle">D</forename><surname>Brawley</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Lancet</title>
		<imprint>
			<biblScope unit="volume">392</biblScope>
			<biblScope unit="page" from="2353" to="2366" />
			<date type="published" when="2018" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b13">
	<analytic>
		<title level="a" type="main">Prostate cancer: diagnosis and management</title>
	</analytic>
	<monogr>
		<title level="j">NICE</title>
		<imprint>
			<date type="published" when="2019" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b14">
	<analytic>
		<title level="a" type="main">Cancer of the prostate: ESMO clinical practice guidelines for diagnosis, treatment and follow-up</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">C</forename><surname>Parker</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">S</forename><surname>Gillessen</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">A</forename><surname>Heidenreich</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><surname>Esmo Guidelines Committee</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Ann Oncol</title>
		<imprint>
			<biblScope unit="volume">26</biblScope>
			<biblScope unit="issue">5</biblScope>
			<biblScope unit="page">69</biblScope>
			<date type="published" when="2015" />
		</imprint>
	</monogr>
	<note>Suppl</note>
</biblStruct>

<biblStruct xml:id="b15">
	<analytic>
		<title/>
	</analytic>
	<monogr>
		<title level="j">European Association of Urology Guidelines: Prostate Cancer</title>
		<imprint>
			<date type="published" when="2019" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b16">
	<analytic>
		<title level="a" type="main">A proportional hazards model for the subdistribution of a competing risk</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">J</forename><forename type="middle">P</forename><surname>Fine</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">R</forename><forename type="middle">J</forename><surname>Gray</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Am Stat Assoc</title>
		<imprint>
			<biblScope unit="volume">94</biblScope>
			<biblScope unit="issue">446</biblScope>
			<biblScope unit="page" from="496" to="509" />
			<date type="published" when="1999" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b17">
	<analytic>
		<title level="a" type="main">The use of restricted mean survival time to estimate the treatment effect in randomized clinical trials when the proportional hazards assumption is in doubt</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">P</forename><surname>Royston</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">M</forename><forename type="middle">K</forename><surname>Parmar</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Stat Med</title>
		<imprint>
			<biblScope unit="volume">30</biblScope>
			<biblScope unit="page" from="2409" to="2421" />
			<date type="published" when="2011" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b18">
	<analytic>
		<title level="a" type="main">Androgen deprivation therapy (ADT) plus docetaxel versus ADT alone in metastatic non-castrate prostate cancer: impact of metastatic burden and long-term survival analysis of the randomized phase 3 GETUG-AFU15 trial</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">G</forename><surname>Gravis</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">J</forename><forename type="middle">M</forename><surname>Boher</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">F</forename><surname>Joly</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Eur Urol</title>
		<imprint>
			<biblScope unit="volume">70</biblScope>
			<biblScope unit="issue">2</biblScope>
			<biblScope unit="page" from="256" to="262" />
			<date type="published" when="2016" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b19">
	<analytic>
		<title level="a" type="main">Characterization of differences between prostate cancer patients presenting with de novo versus primary progressive metastatic disease</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">A</forename><surname>Finianos</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">K</forename><surname>Gupta</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">B</forename><surname>Clark</surname></persName>
		</author>
		<idno type="DOI">10.1016/j.clgc.2017.08.006</idno>
	</analytic>
	<monogr>
		<title level="j">Clin Genitourin Cancer</title>
		<imprint>
			<date type="published" when="2017" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b20">
	<analytic>
		<title level="a" type="main">Importance of non-regional lymph nodes in assigning risk in primary metastatic prostate cancer</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">A</forename><surname>Ali</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">A</forename><surname>Hoyle</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">H</forename><surname>Mistry</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">N</forename><forename type="middle">W</forename><surname>Clarke</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">BJU Int</title>
		<imprint>
			<biblScope unit="volume">123</biblScope>
			<biblScope unit="issue">1</biblScope>
			<biblScope unit="page" from="65" to="73" />
			<date type="published" when="2019" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b21">
	<analytic>
		<title level="a" type="main">Adding abiraterone or docetaxel to long-term hormone therapy for prostate cancer: directly randomised data from the STAMPEDE multi-arm, multi-stage platform protocol</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">M</forename><forename type="middle">R</forename><surname>Sydes</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">M</forename><forename type="middle">R</forename><surname>Spears</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">M</forename><forename type="middle">D</forename><surname>Mason</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Ann Oncol</title>
		<imprint>
			<biblScope unit="volume">29</biblScope>
			<biblScope unit="issue">5</biblScope>
			<biblScope unit="page" from="1235" to="1248" />
			<date type="published" when="2018" />
		</imprint>
	</monogr>
</biblStruct>

				</listBibl>
			</div>
		</back>
	</text>
</TEI>
